PEG-MODIFIED HUMAN INTERFERON β-1a MOLECULE WITH ANTIVIRAL, IMMUNOMODULATORY AND ANTIPROLIFERATIVE ACTIVITY, WITH IMPROVED STABILITY, REDUCED IMMUNOGENICITY, IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS, SUITABLE FOR MEDICAL USE, AND IMMUNOBIOLOGICAL FORMULATION BASED THEREON

FIELD: biotechnologies. SUBSTANCE: invention relates to biotechnologies, especially to obtaining PEG conjugate and human interferon-β1a, and may be used in medicine. Attachment of a PEG linear molecule 20-40 kD to human interferon-β-1a produced a conjugate of formula (I): , wherein: n - an integer from 454 to 909; m - an integer ≥ 4; IFN is a natural or recombinant human interferon-β-1a. Compared to natural human interferonβ-1a, the conjugate of formula (I) provides a higher stability, reduced immunogenicity and improved pharmacokinetic and pharmacodynamic parameters. EFFECT: conjugate may be used for treatment of various autoimmune, viral, and oncological diseases. 28 cl, 10 dwg, 9 tbl, 20 ex